Open an account

Nyxoah SA

NYXH · NYSE

$0.8344+$0.0124 (+1.51%)TodayMarket closed ·
Prev close $0.822

About NYXH

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 154 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Employees
154
Headquarters
Mont-Saint-Guibert, Brabant-Wallon
Listed
Sep 18, 2020
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
nyxoah.com

NYXH key statistics

Market cap
74.55M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
217.12K
Volume
181.00K
Open price
$0.8627
High today
$0.8675
Low today
$0.80
52 Week high
$5.92
52 Week low
$0.8011

Nyxoah SA (NYXH) at a glance

Nyxoah SA (NYXH) last traded at $0.8344, with a market cap of 74.55M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.80 and $0.8675. The current price is 4.3% above the day's low and 3.8% below its high.

Volume so far is 181.00K shares, in line with the average of 217.12K shares a day.

Over the past year Nyxoah SA has ranged from $0.8011 to $5.92, and now sits 1% of the way up that range.

Nyxoah SA met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.578 per share against an estimate of -$0.3946.

The average analyst price target is $4.34, 420.1% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 6 analystsAvg $4.34
Low
$1.59
Now
$0.8344
High
$6.73

NYXH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 11.4% on average.

  1. Q3 FY24: reported -$0.496 per share against an estimate of -$0.479
  2. Q4 FY24: reported -$0.463 per share against an estimate of -$0.473
  3. Q1 FY25: reported -$0.598 per share against an estimate of -$0.4895
  4. Q2 FY25: reported -$0.551 per share against an estimate of -$0.581
  5. Q3 FY25: reported -$0.63 per share against an estimate of -$0.5999
  6. Q4 FY25: reported -$0.586 per share against an estimate of -$0.5554
  7. Q1 FY26: reported -$0.369 per share against an estimate of -$0.5057
  8. Q2 FY26: reported -$0.578 per share against an estimate of -$0.3946

NYXH news

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Vandana Singh

    What's Going On With Nyxoah Stock Tuesday?

  • Press releaseGlobe Newswire

    Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

  • Chris Katje

    Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. – NYXH

  • Examining the Future: Nyxoah's Earnings Outlook

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

Similar companies

Companies in the same industry as Nyxoah SA

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.